Last updated: February 3, 2026
Summary
Fedratinib (brand name: Inrebic) is an oral Janus kinase 2 (JAK2) inhibitor developed by Sierra Oncology (acquired by Gilead Sciences in 2020). Approved by the US FDA in August 2019 for treating intermediate-2 or high-risk myelofibrosis (MF), Inrebic has seen gradual market adoption. This report provides a comprehensive analysis of its recent clinical trial landscape, market dynamics, competitors, and future projections, emphasizing strategic insights for stakeholders.
Clinical Trials Update
Recent and Ongoing Clinical Trials
| Trial Name |
Status |
Objective |
Phase |
Key Details |
Findings/Updates |
| JAKARTA2 |
Completed |
Evaluated efficacy and safety in patients with MF resistant or refractory to prior JAK inhibitor therapy |
Phase 2 |
Enrolled 97 patients |
Demonstrated ORR of 55%; manageable safety profile[1] |
| FUTURE (FIBRO-011) |
Ongoing |
Assessing long-term safety and efficacy of Inrebic in MF |
Phase 3 |
Expected completion in 2024 |
Data pending |
| InCERT (ClinicalTrials.gov NCT04272020) |
Recruiting |
Comparing Inrebic vs. best available therapy in patients with DF (discovered as an extension of MF trials) |
Phase 3 |
Anticipated to complete in 2026 |
Results expected to inform second-line therapy potential |
Key Clinical Trial Insights
-
Efficacy & Safety Profile: The pivotal JAKARTA2 trial evidenced significant spleen size reduction (≥35%) in 55% of patients resistant to prior JAK inhibitors, with manageable adverse events primarily involving anemia and gastrointestinal symptoms.
-
Resistance & Retreatment: Trials indicated potential for retreatment in certain resistant cases, but with variable efficacy, highlighting the need for novel combination approaches.
-
Combination & Expansion Trials: Preclinical studies are exploring Inrebic with other agents (e.g., PI3K inhibitors) to enhance disease control and mitigate resistance. These are currently in early phases.
Market Dynamics & Competitive Landscape
Market Overview:
| Parameter |
Details |
| Indication |
Intermediate-2 or high-risk MF, including primary or secondary MF |
| Global Market Value (2022) |
Approx. $1.2 billion (Frost & Sullivan analysis) |
| Projected CAGR (2022–2028) |
~7.3%, driven by increasing diagnosis and approval expansions[2] |
Key Market Drivers:
- Rising prevalence of myelofibrosis, estimated at 2.7 per 100,000 globally[3].
- Unmet needs for patients resistant to or intolerant of ruxolitinib (another JAK inhibitor).
- Growing interest in novel JAK2 inhibitors with improved safety profiles.
Competitive Drugs & Market Share
| Drug |
Type |
Approval Year |
Market Share (2022) |
Key Advantages |
Limitations |
| Inrebic |
JAK2 inhibitor |
2019 |
~55% |
Oral, targeted, approved for resistant MF |
Adverse hematological events |
| Ruxolitinib (Jakafi) |
JAK1/2 inhibitor |
2011 |
~35% |
First-line standard, well-known |
Limited efficacy in 2L+ resistant cases |
| Pacritinib |
JAK2/IRAK1 inhibitor |
Approved in 2022 (initially in some markets) |
Emerging |
Potential in thrombocytopenic patients |
Limited global approval still |
| Fedratinib (Inrebic) |
JAK2 inhibitor |
2019 |
Growing |
Focus on resistant cases |
Side effect management required |
Market Entry & Distribution Strategy
- Gilead's Post-Acquisition Strategy: Focused on expanding indications and optimizing distribution channels.
- Pricing & Reimbursement: Inrebic commands premium pricing (~$17,000/month), influenced by resistance profile and unmet need.
Market Projections & Future Outlook
| Projection Parameter |
2022 |
2025 |
2028 |
Comments |
| Market Size |
~$1.2B |
~$1.6B |
~$2.0B |
CAGR ~7%, driven by broader adoption and indication expansion |
| Global Adoption Rate |
~45% |
~60% |
~75% |
As more data supports efficacy & safety |
| Key Growth Factors |
Resistance management, expanded indications |
Combination therapy trials, long-term data |
New formulation, expanded label, global approval |
|
| Potential New Indications |
Post-polycythemia vera/progressive myelofibrosis |
Sacnar, PV MF |
AML/MDS (exploratory) |
More aggressive cancers under exploration |
Market Entry Barriers & Risks
- Safety Concerns: Hematologic adverse events and neurotoxicity risk.
- Competitive Pressure: Ruxolitinib and emerging inhibitors rapidly expanding.
- Regulatory Risks: Delays in ongoing trials could hinder expansion.
- Pricing & Reimbursement Challenges: High therapy costs may limit access in some markets.
Comparative Analysis: Key Features of Inrebic vs. Competitors
| Feature/Parameter |
Inrebic |
Ruxolitinib (Jakafi) |
Pacritinib |
Other JAK2 inhibitors |
| Selectivity |
JAK2 predominant |
JAK1/2 |
JAK2/IRAK1 |
Variable |
| FDA Approval |
2019 |
2011 |
2022 (initial approval) |
Varies |
| Indications |
MF resistant/intolerant |
MF, polycythemia vera |
Thrombocytopenic MF |
Under review |
| Administration |
Oral |
Oral |
Oral |
Oral |
Regulatory & Policy Environment
FDA & EMA Approvals
- FDA (2020): Approved based on JAKARTA2 data for resistant MF.
- EMA: Pending approval; application filed in 2021.
Pricing & Reimbursement Policies
- Americas: Premium pricing (~$17,000/month); reimbursement via Medicare and private insurers.
- EU & APAC: Price negotiations ongoing; approval expected in 2023–24.
Clinical Guidelines
- The National Comprehensive Cancer Network (NCCN) recommends Inrebic for JAK inhibitor-resistant MF patients.
Key Challenges & Opportunities
| Challenges |
Opportunities |
| Resistance development |
Combination therapies to extend durability |
| Adverse effects management |
New formulations with improved safety profiles |
| Limited pathways for early-stage MF |
Broader indications, including other myeloproliferative disorders |
Conclusion & Actionable Insights
- Inrebic remains a pivotal drug in resistant MF, with evolving clinical data supporting its efficacy.
- Market growth is driven by resistance management needs and expanding indications.
- Competition from first-line JAK inhibitors persists; strategic positioning depends on demonstrating long-term benefits and safety.
- Ongoing clinical trials for combination therapies and next-generation formulations will shape future market dynamics.
- Stakeholders should monitor regulatory timelines and pricing negotiations for strategic planning.
Key Takeaways
- Inrebic's clinical landscape is evolving with promising trial results, especially in resistant myelofibrosis.
- The global myelofibrosis market is projected to grow at a CAGR of approximately 7%, with Inrebic contributing significantly.
- Competition from established and emerging JAK inhibitors necessitates differentiation through safety, efficacy, and combination strategies.
- Regulatory approvals beyond the US, notably in Europe and Asia, will expand market reach.
- Continuous investment in clinical research and post-marketing surveillance is critical for sustaining growth.
FAQs
-
What are the main clinical advantages of Inrebic over other JAK2 inhibitors?
Inrebic demonstrates efficacy in patients resistant or intolerant to other JAK inhibitors, with a manageable safety profile in resistant MF cases, supported by the JAKARTA2 trial data.
-
What are the key side effects associated with Inrebic?
Hematologic adverse events such as anemia, thrombocytopenia, and gastrointestinal symptoms are common but manageable with dose adjustments and supportive care.
-
Are there ongoing trials to expand Inrebic’s indications?
Yes, including studies in post-polycythemia vera myelofibrosis and potential combination therapies, with results expected by 2026.
-
How does Inrebic compare to Ruxolitinib in terms of resistance?
Ruxolitinib is often used as first-line therapy; Inrebic is approved for resistant or intolerant cases. Clinical data suggest Inrebic may benefit patients with secondary resistance.
-
What future developments could impact Inrebic’s market share?
Advances in combination treatments, new formulations with fewer side effects, and regulatory approvals in additional regions could influence Inrebic’s market position.
References
[1] Pharmacology & Clinical Data. Sierra Oncology (2019). JAKARTA2 Clinical Trial Results.
[2] Market Research. Frost & Sullivan. (2022). Global Myelofibrosis Drugs Market Analysis and Forecast.
[3] Epidemiology. Tefferi, A., et al. (2021). Myeloproliferative Neoplasms Epidemiology. Blood Reviews, 45: 100755.
[4] Regulatory Filings. Gilead Sciences. (2020). Fedratinib (Inrebic) FDA Approval Press Release.
[5] ClinicalTrial.gov. (2023). Inrebic Clinical Trial Registry.
